Title: Quinidine: potent inhibition of sparteine and debrisoquine oxidation in vivo.
Abstract: British Journal of Clinical PharmacologyVolume 22, Issue 2 p. 199-200 Free Access Quinidine: potent inhibition of sparteine and debrisoquine oxidation in vivo. T. Inaba, T. InabaSearch for more papers by this authorRE Tyndale, RE TyndaleSearch for more papers by this authorWA Mahon, WA MahonSearch for more papers by this author T. Inaba, T. InabaSearch for more papers by this authorRE Tyndale, RE TyndaleSearch for more papers by this authorWA Mahon, WA MahonSearch for more papers by this author First published: August 1986 https://doi.org/10.1111/j.1365-2125.1986.tb05251.xCitations: 56AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References Eichelbaum, M. (1984). Polymorphic drug oxidation in humans. Fed. Proc., 43, 2298–2302. CASPubMedWeb of Science®Google Scholar Inaba, T., Vinks, A., Otton, S. V. & Kalow, W. (1983). Comparative pharmacogenetics of sparteine and debrisoquine. Clin. Pharmac. Ther., 33, 394–399. 10.1038/clpt.1983.51 CASPubMedWeb of Science®Google Scholar Inaba, T., Jurima, M., Mahon, W. A. & Kalow, W. (1985). In vitro inhibition studies of two isozymes of human liver cytochrome P-450. Drug Metab. Disp., 13, 443–448. CASPubMedWeb of Science®Google Scholar Kalow, W.: Pharmacoanthropology. II. Drug Metabolism. Fed. Proc., 43, 2326–2331. Google Scholar Otton, S. V., Inaba, T. & Kalow, W. (1984). Competitive inhibition of sparteine oxidation in human liver by β-adrenoceptor antagonists and other cardiovascular drugs. Life Sci., 34, 73–80. 10.1016/0024-3205(84)90332-1 CASPubMedWeb of Science®Google Scholar Leemann, T., Dayer, P. & Meyer, U. A. (1986). Single-dose quinidine treatment inhibits metoprolol oxidation in extensive metabolizers. Eur. J. clin. Pharmac. (in press). 10.1007/BF00615971 Web of Science®Google Scholar Lennard, M. S. (1985). Oxidation phenotype and the metabolism and action of beta-blockers. Klin. Wochenschr., 63, 285–292. 10.1007/BF01731972 CASPubMedWeb of Science®Google Scholar Citing Literature Volume22, Issue2August 1986Pages 199-200 ReferencesRelatedInformation